一位 Mylan Laboratories 公司的官员要求美国国会遏制品牌药公司销售授权非专利药，从而保护仿制药商。 Mylan 公司的 Heather Bresch 说，授权非专利药是“削弱”仿制药业的一种策略，他还说如果没有来自于仿制药的竞争，品牌药公司将永远不会提供低价的替代产品。
---更多详情 The Washington Post /Reuters
Congress urged to clear path for generic drugs
By Susan Heavey
Reuters
Thursday, July 20, 2006; 7:14 PM
WASHINGTON (Reuters) - Congress should act to
protect generic drugmakers from brand-name company
tactics that thwart competition and keep cheaper
medicines from U.S. consumers,
a generic manufacturer said on Thursday.
